<DOC>
	<DOCNO>NCT02910583</DOCNO>
	<brief_summary>This study determine clinical minimum residual disease ( MRD ) response combination ibrutinib plus venetoclax subject treatment-naive chronic lymphocytic leukemia ( CLL ) /small lymphocytic lymphoma</brief_summary>
	<brief_title>Ibrutinib Plus Venetoclax Patients With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Diagnosis CLL/SLL meet IWCLL diagnostic criterion ( Hallek 2008 ) , active disease meeting least 1 IWCLL criterion require treatment . Measurable nodal disease compute tomography ( CT ) Adequate hepatic , renal function Adequate hematologic function absolute neutrophil count &gt; 750/µL platelet count &gt; 30,000 /μL hemoglobin &gt; 8.0 g/dL Any prior therapy use treatment CLL/SLL Known allergy xanthine oxidase inhibitor and/or rasburicase subject risk TLS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>